Genmab — December 2012
-
I emissionskursen
-
Jeg går på talerstolen næsten gang (igen)
-
De har rigeligt plads. Tror han fedtspiller arzerra
-
Om 5 år så
-
Ses
-
-
Mon ikke vi får noget senere i aften på dette indlæg https://ash.confex.com/ash/2012/webprogram/Paper46584.html
-
lige kommet en pressemeddelelse
-
2 PR og en MR på de 3 24 mg patienter
-
In pts with relapsed or refractory MM treated with daratumumab, a marked reduction in paraprotein and bone marrow plasma cells was observed in the higher dose cohorts. This has not previously been demonstrated with a single-agent monoclonal antibody in MM. No unexpected buildup of daratumumab was seen and in pts treated with 4mg/kg and upwards the observed plasma concentrations were close to those predicted
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind